These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 24494842)

  • 1. Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus.
    Elsharkawy AM
    Aliment Pharmacol Ther; 2014 Mar; 39(5):543-4. PubMed ID: 24494842
    [No Abstract]   [Full Text] [Related]  

  • 2. Commentary: detection of low level viraemia in telaprevir-based triple therapy for hepatitis C virus - authors' reply.
    Maasoumy B; Wedemeyer H
    Aliment Pharmacol Ther; 2014 Mar; 39(5):544-5. PubMed ID: 24494844
    [No Abstract]   [Full Text] [Related]  

  • 3. Detection of low HCV viraemia by repeated HCV RNA testing predicts treatment failure to triple therapy with telaprevir.
    Maasoumy B; Cobb B; Bremer B; Luk K; Halfon P; Aslam S; Manns MP; Cornberg M; Wedemeyer H
    Aliment Pharmacol Ther; 2014 Jan; 39(1):85-92. PubMed ID: 24206524
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Further evolution of hepatitis C treatment: individualized therapy.
    Smith JR; Herrera JL
    Am J Gastroenterol; 2000 Sep; 95(9):2383. PubMed ID: 11007249
    [No Abstract]   [Full Text] [Related]  

  • 5. Direct-acting antiviral-based triple therapy on alpha-fetoprotein level in chronic hepatitis C patients.
    Takayama K; Furusyo N; Ogawa E; Ikezaki H; Shimizu M; Murata M; Hayashi J
    World J Gastroenterol; 2015 Apr; 21(15):4696-706. PubMed ID: 25914481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dynamic changes in HCV RNA levels and viral quasispecies in a patient with chronic hepatitis C after telaprevir-based treatment.
    de Bruijne J; Sullivan JC; Kieffer TL; Botfield M; Shames B; Schinkel J; Molenkamp R; Weegink C; Reesink H
    J Clin Virol; 2012 Feb; 53(2):174-7. PubMed ID: 22138301
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hepatitis C virus. Preface.
    Reddy KR; Kaplan DE
    Clin Liver Dis; 2008 Aug; 12(3):xiii-xiv. PubMed ID: 18625424
    [No Abstract]   [Full Text] [Related]  

  • 8. Kinetics of hepatitis C virus RNA decay, quasispecies evolution and risk of virological failure during telaprevir-based triple therapy in clinical practice.
    Cento V; Tontodonati M; Di Maio VC; Bellocchi MC; Valenti F; Manunta A; Fortuna S; Armenia D; Carioti L; Antonucci FP; Bertoli A; Trave F; Cacciatore P; Angelico M; Navarra P; Neumann AU; Vecchiet J; Parruti G; Babudieri S; Perno CF; Ceccherini-Silberstein F
    Dig Liver Dis; 2015 Mar; 47(3):233-41. PubMed ID: 25637450
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
    Swiss Association for the Study of the Liver
    Swiss Med Wkly; 2012; 142():w13516. PubMed ID: 22367957
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatitis C genotype 1b and 4 cured after telaprevir-based therapy.
    Pérez-Parente D; Suárez-Ordóñez S; Suárez-Santamaría M; Morano-Amado LE
    Rev Esp Enferm Dig; 2015 Apr; 107(4):251. PubMed ID: 25824935
    [No Abstract]   [Full Text] [Related]  

  • 11. Triple antiviral therapy in hepatitis C virus infection with or without mixed cryoglobulinaemia: a prospective, controlled pilot study.
    Gragnani L; Fabbrizzi A; Triboli E; Urraro T; Boldrini B; Fognani E; Piluso A; Caini P; Ranieri J; Monti M; Laffi G; Zignego AL
    Dig Liver Dis; 2014 Sep; 46(9):833-7. PubMed ID: 24953206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Closing in on the target: sustained virologic response in hepatitis C virus genotype 1 infection response-guided therapy.
    Lontok E; Mani N; Harrington PR; Miller V
    Clin Infect Dis; 2013 May; 56(10):1466-70. PubMed ID: 23362287
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Telaprevir: a hepatitis C NS3/4A protease inhibitor.
    Matthews SJ; Lancaster JW
    Clin Ther; 2012 Sep; 34(9):1857-82. PubMed ID: 22951253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Telaprevir activity in treatment-naive patients infected hepatitis C virus genotype 4: a randomized trial.
    Benhamou Y; Moussalli J; Ratziu V; Lebray P; De Backer K; De Meyer S; Ghys A; Luo D; Picchio GR; Beumont M
    J Infect Dis; 2013 Sep; 208(6):1000-7. PubMed ID: 23801602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Early determination of hepatitis C virus RNA may help to decide the duration of therapy for chronic hepatitis C virus genotype 2/3 infection.
    Lagging M; Alsiö A; Langeland N; Pedersen C; Färkkilä M; Buhl MR; Mørch K; Hellstrand K; Norkrans G
    Hepatology; 2011 Mar; 53(3):1067-8. PubMed ID: 21374685
    [No Abstract]   [Full Text] [Related]  

  • 16. Telaprevir can be successfully and safely used to treat older patients with genotype 1b chronic hepatitis C.
    Furusyo N; Ogawa E; Nakamuta M; Kajiwara E; Nomura H; Dohmen K; Takahashi K; Satoh T; Azuma K; Kawano A; Tanabe Y; Kotoh K; Shimoda S; Hayashi J;
    J Hepatol; 2013 Aug; 59(2):205-12. PubMed ID: 23542346
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The real impact of telaprevir dosage on the antiviral and side effects of telaprevir, pegylated interferon and ribavirin therapy for chronic hepatitis C patients with HCV genotype 1.
    Oze T; Hiramatsu N; Yakushijin T; Yamada R; Harada N; Morishita N; Oshita M; Mita E; Ito T; Inui Y; Inada M; Tamura S; Yoshihara H; Imai Y; Kato M; Miyagi T; Yoshida Y; Tatsumi T; Kasahara A; Hayashi N; Takehara T
    J Viral Hepat; 2015 Mar; 22(3):254-62. PubMed ID: 25081140
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Telaprevir: new possibilities for antiviral treatment in patients with chronic hepatitis C].
    Nikitin IG; Gogova LM; Baikova IE; Kislyakov VA; Volynkina VM
    Ter Arkh; 2012; 84(11):75-80. PubMed ID: 23252254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Early phase viral kinetics of chronic hepatitis C patients receiving telaprevir-based triple therapy: a comparison of two real-time PCR assays.
    Ogawa E; Furusyo N; Murata M; Toyoda K; Eiraku K; Shimizu M; Harada Y; Mitsumoto F; Takayama K; Okada K; Kainuma M; Hayashi J
    Antiviral Res; 2013 Aug; 99(2):119-24. PubMed ID: 23684903
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of low-level HCV viraemia at week 24 on HCV treatment response in genotype 1 patients.
    Baleriola C; Rawlinson WD; Dore GJ; Chaverot S; Stelzer-Braid S; Yoshihara M; Crawford D; Sievert W; McCaughan G; Weltman M; Cheng W; Rizkalla B; Dubois D; Thommes J; Roberts S
    Antivir Ther; 2011; 16(2):173-80. PubMed ID: 21447866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.